Persistence pays off as Erbitux finally wins approval

February 23, 2004

Erbitux, the colorectal cancer drug once blighted by one of the biggest ever regulatory scandals has been granted marketing approval …

Cystic fibrosis inhaler to gain European approvals

February 23, 2004

UK drug delivery specialist Profile Therapeutics says it expects marketing approval for its new inhaled cystic fibrosis drug in eight …

Fast track surgery supplier chosen

February 19, 2004

Mercury Healthcare has been chosen as the preferred supplier to run five new NHS fast-track surgery centres.Routine general surgery will …

A new kind of weighting

February 12, 2004

A little knowledge goes a long way

February 12, 2004

Probably one of the biggest problems the pharmaceutical industry has had to overcome over the years is the question of …

Escape routes diminishing for Aventis

February 12, 2004
Sanofi-Aventis, acqisition, merger

 Aventis’ chances of sidestepping the hostile takeover bid from Sanofi-Synthelabo are looking increasingly less likely as the ‘alternative scenarios’ it …

Government signals shift away from NHS targets

February 12, 2004

The government has signalled that the profusion of targets introduced to measure NHS performance have done their job, and says …

It’s good to talk, says Europe’s ambitious regulator

February 12, 2004

Europe's medicines regulator has unveiled its new long-term strategy to improve its work on human medicines as it prepares to …

War of words over atypicals link to diabetes

February 5, 2004

Pfizer and Eli Lilly have tried to distance their products from renewed claims that atypical antipsychotics are linked to an …

Strong Roche says no to mergers

February 5, 2004

Roche is set for a strong return to growth in 2004 and says it should be counted out of growing …

AZ switches Symbicort agency

February 5, 2004

AstraZeneca has taken on a new PR agency to spearhead a new two-year communications campaign for its respiratory brand treatment …

Zeltia to press ahead with rejected cancer drug

February 4, 2004

Zeltia has unveiled a three-year business plan to put itself back on track after lead cancer drug Yondelis was rejected …

The Gateway to Local Adoption Series

Latest content